Clinical Trial Update: Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Compound Sodium Alginate Double Action Chewable Tablet for symptomatic relief in gastroesophageal reflux disease and dyspepsia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyspepsia
• Gastroesophageal Reflux Disease

Drugs mentioned

• Compound Sodium Alginate Double Action Chewable Tablet (sodium alginate)

Snippet

Sponsor: Reckitt Benckiser Healthcare (UK) Limited | Conditions: Gastroesophageal Reflux Disease, Dyspepsia | Phase 3 | Status: COMPLETED | Results posted: 2025-03-13